The shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) are trading at $3.41 after going up by $0.48. This increase in stock price represents a 52.91% rise from its 52-week low price of $2.23 which was attained back on May 09, earlier this year. But the price still lags -124.93% behind the highest price mark of $7.67 attained on 2019-09-11. CPRX hasnt been performing well over the past few days, with its price dropping by -13.67% during that time frame. The same cant be said for its performance over the past 90 days as it dropped by roughly -20.7% while its overall gain so far this year stands at 14.05%. Looking further than that, its shares have gone down by just -9.07% this year to date. Over the next one year, Catalyst Pharmaceuticals, Inc. shares are expected to reach $9.17, which means that it is expected to rise by 168.91% from its current position.

Out of 6 Wall Street analysts, 6 (100%) of them have rated CPRX as a Buy. The remaining 0 brokerage firms which represent 0% that recommend investors to Hold while it wasnt rated as a Sell by any analyst. Catalyst Pharmaceuticals, Inc. shares held by institutional investors have dropped by 62.8% over the past three months. During that same time, 30 institutions invested in the stock, while 77 added the shares to their existing portfolios. 51 institutional investors reduced their shares in the compnay with only 17 selling their total positions.

The trading volume of CPRX, when compared with its 50-day average volume of 2,058,700, has gone up by 94.57% after additional 4,005,597 shares were sold. The price of the stock is -21.91% below its 20-day SMA, which means that it is currently in a bearish trend. In addition to that, it is also -20.63% below its 50-day SMA, and -27% below its 200-day SMA. At the moment, Catalyst Pharmaceuticals, Inc.s ROE stands around 15.5% and market experts are of the view that the companys earnings per share growth will stand at roughly 0% annually till 2023. If that happens, then it would be off by just -4.4% when compared to the previous five years.

The stock is expected to encounter its first resistance point at $3.78, which is just 9.79% above its current position while the next resistance stands at $4.16, 18.03% from its current price. If CPRX fails to break the immediate resistance, then it is in danger of seeing its price drop to $2.18. The stocks 14-day MACD is -0.69, which means that it is currently in a downward trading trend. Its two weeks RSI meanwhile stands at 39.52, indicating that the stock has been neutral while its 20-day historical volatility reads 127.81%, which is higher than its 50-day equivalent (94.1%).

Vir Biotechnology, Inc. has seen its stock (NASDAQ:VIR) climbed by 16.12% over the past few days and is now trading around at $43.66 on the Wall Street in the intra-day deal. During that period, roughly 1.1 Million VIR shares were traded on NASDAQ. The 90-days average daily trading volume of the stock has been around 821. Thousand but 293.5 Thousand extra shares were traded on that day. VIR has gone up by 274.76% from its 52-week low of $11.65.

Over the past one month, the stock has performed well as it surged by 129.91% during that period. This led to its price increase to stand at 247.2% since the start of the year. The situation still not remains the same when its performance over the past few days was reviewed as it lost -4.46% of its value in the past week. This recent development has seen its 12-month potential target price placed at $26.33, which means that it is expected to decrease by -39.69% from its current price. Of the 5 Wall Street analysts that rated the stock, 60% (3 analysts) have rated VIR as a Buy while the remaining 20% (1 analysts) rated it as a Hold, with 20% (1 analysts) rated the stock as a Sell.

The company has been making use of ROE that stands around 0%, with market experts of the view that their EPS over the next five years will likely fall by 0% annually. This will be a drop from the 0% growth achieved over the past five years. At the moment, VIR is on a bullish trend, up 35.33% from its SMA20, 86.35% above its SMA50, and 140.13% above its SMA200. VIR shares held by institutional investors have jumped by 63.4% over the past three months. A total of 37 institutional investors entered new positions while 37 added to their existing portfolio. 0 hedge funds lowered their positions in the stock with only 0 selling their shares entirely.

VIRs 9-day MACD currently stands at -1.58, which means that the price is on a downward trend. The stocks 9-day RSI score reads 59.6, signaling that the stock is neutral. Its 20-day historical volatility currently stands at 358.49% and is on the upside when compared with its 50-day historical volatility which is 221.75%. A look at VIRs daily chart reveals that its first resistance point stands at $47.18, a 7.46% rise from its current position, while the second resistance point is 13.89% ($50.7) ahead of its current position. If the share fails to break the immediate resistances, it could drop down to $29.58.

Go here to read the rest:
This is The Biggest Threat To Catalyst Pharmaceuticals, Inc. (CPRX), Vir Biotechnology, Inc. (VIR) - The RVC News